NOVO NORDISK B

Novo Nordisk’s shares fell after the Phase‑3 ZEUS study showed Ziltivekimab lowered inflammatory biomarkers but missed cardiovascular benefit, impacting future approvals and market outlook.

New Nordisk’s pivotal earnings week: after a ZEUS flop, the firm ramps up 2026 capacity, boosts revenue outlook and holds the wheel of its GLP‑1 leaders, Wegovy & Ozempic.

Novo Nordisk’s failed cardiovascular Phase‑III trial reveals platform risks, regulatory shifts, and new digital‑health, gene‑editing opportunities to drive future growth.

New Nordisk shares fell as the Phase‑III trial of Ziltivekimab failed to reduce cardiovascular events, highlighting the challenges of anti‑inflammatory heart therapies and the company’s reliance on core GLP‑1 products.

Investors weigh Novo Nordisk’s €45 share price and GLP‑1 obesity strategy, noting slowing uptake of Wegovy and Zepbound, new combination therapies, and a 2030‑2033 patent cliff that could reshape market dynamics.

How Novo Nordisk’s Wegovy growth, cell‑based platform, and legal challenges shape its future in obesity and diabetes markets.

Novo Nordisk shares rise 3% in Copenhagen amid cautious optimism, as investors weigh GLP‑1 success, new amylin therapy, and competitive pressures in the obesity‑drug market.

Legal showdown: Novo Nordisk sues Eli Lilly over misleading weight‑loss ads, demanding a court order to stop comparative claims and protect market share in the $100 billion obesity‑drug race.

Explore how Novo Nordisk’s share slide mirrors fierce competition in obesity drugs, Eli Lilly’s upcoming therapy, and shifting peptide regulations.

Discover how Novo Nordisk’s new oral GLP‑1 tablet transforms obesity treatment, boosting patient adherence, clinical outcomes, and investor confidence.